The company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.
Artiva Biotherapeutics agreed to sell 23,871,526 shares at $11.52 each, plus pre-funded warrants for 2,170,138 shares. The company's last reported sale price was $12.52 on May 7, 2026.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $301.5 million, plus short-term investments of $47.9 million, $349.4 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Artiva Biotherapeutics
Has Artiva Biotherapeutics raised money recently?
Our latest story on this, dated Aug 6, 2026: "Artiva Biotherapeutics files $400,000,000 shelf with $100,000,000 ATM program". The story links the filing or release it is based on. Read the story.
Has Artiva Biotherapeutics cut staff?
Our latest story on this, dated Oct 27, 2026: "Artiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Artiva Biotherapeutics?
Artiva Biotherapeutics, Inc. trades under the ticker ARTV on NASDAQ.
Where is Artiva Biotherapeutics listed?
Artiva Biotherapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Artiva Biotherapeutics?
The SEC Central Index Key (CIK) for Artiva Biotherapeutics, Inc. is 1817241. Its filings are on SEC EDGAR.
How many shares does Artiva Biotherapeutics have outstanding?
48,890,121 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Artiva Biotherapeutics listed under?
Our directory records Artiva Biotherapeutics, Inc. under United States.
What does Artiva Biotherapeutics do?
Our directory classifies Artiva Biotherapeutics, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
What is the ISIN of Artiva Biotherapeutics?
The ISIN recorded for Artiva Biotherapeutics, Inc. is US04317A1079.
Does aibio.space cover Artiva Biotherapeutics?
aibio.space lists Artiva Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Artiva Biotherapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Artiva Biotherapeutics's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Artiva Biotherapeutics profitable?
Artiva Biotherapeutics, Inc. reported a net loss of $83.9 million for the fiscal year ended Dec 31, 2025, and used $76.8 million of cash in operations, per its annual report to the SEC.
How much does Artiva Biotherapeutics spend on research and development?
$69.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Artiva Biotherapeutics have?
$349.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Artiva Biotherapeutics
Members talk about Artiva Biotherapeutics (ARTV). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Artiva Biotherapeutics, newest first. Each line links the filing it comes from.
Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ARTV on TradingView.
SEC filings and registration
SEC name
Artiva Biotherapeutics, Inc.
CIK
1817241
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
ARTV (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
Phone
(858) 267-4467
Shares outstanding
48,890,121 as of 2026-07-31 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Artiva Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ARTV, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio